[go: up one dir, main page]

US20080019926A1 - Lung Surfactant Supplements - Google Patents

Lung Surfactant Supplements Download PDF

Info

Publication number
US20080019926A1
US20080019926A1 US11/578,673 US57867305A US2008019926A1 US 20080019926 A1 US20080019926 A1 US 20080019926A1 US 57867305 A US57867305 A US 57867305A US 2008019926 A1 US2008019926 A1 US 2008019926A1
Authority
US
United States
Prior art keywords
fluorocarbon
composition
dppc
emulsion
pfob
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/578,673
Other languages
English (en)
Inventor
Marie-Pierre Krafft
Thierry Vandamme
Frederic Gerber
Osamu Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Strasbourg
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/578,673 priority Critical patent/US20080019926A1/en
Assigned to UNIVERSITE LOUIS PASTEUR INDUSTRIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE reassignment UNIVERSITE LOUIS PASTEUR INDUSTRIE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GERBER, FREDERIC, SHIBATA, OSAMU, KRAFFT, MARIE-PIERRE, VANDAMME, THIERRY
Publication of US20080019926A1 publication Critical patent/US20080019926A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant

Definitions

  • the present invention relates generally to lung surfactant compositions and methods for treating pulmonary diseases.
  • the invention specifically discloses the use of biocompatible highly fluorinated compounds, including fluorocarbons in the treatment of various pulmonary conditions.
  • the native lung surfactant consists of a complex mixture of phospholipids, neutral lipids and proteins.
  • the surfactant comprises roughly 90% lipids and 10% proteins with a lipid composition of 55% dipalmitoylphosphatidylcholine (DPPC), 25% phosphatidylcholine (PC), 12% phosphatidylglycerol (PG), 3.5% phosphatidylethanolamine (PE), sphingomyelin and phosphatidylinositol (PI).
  • DPPC dipalmitoylphosphatidylcholine
  • PC 25% phosphatidylcholine
  • PG 12% phosphatidylglycerol
  • PE 3.5% phosphatidylethanolamine
  • PI sphingomyelin and phosphatidylinositol
  • the lung surfactant functions are to reduce the surface tension within the alveoli. It helps to mediate the transfer of oxygen and carbon dioxide, promotes alveolar expansion and covers the surface of the lung alveoli. Reduced surface tension permits the alveoli to be held open under low pressure. In addition, the lung surfactant supports alveolar expansion by varying the surface tension depending on alveolar size.
  • Surfactant supplements are presently used therapeutically when the lung surfactant present does not allow efficient respiratory function.
  • Surfactant supplementation is commonly used to treat Respiratory Distress Syndrome (RDS), when surfactant deficiencies compromise pulmonary function. While RDS is primarily a disease of newborn infants, an adult form of the disease, Adult Respiratory Distress Syndrome (ARDS), has many characteristics in common with RDS, thus lending itself to similar therapies. More generally, there exist various forms of acute lung injuries that are related to a dysfunction of the pulmonary surfactant.
  • RDS Respiratory Distress Syndrome
  • ARDS Adult Respiratory Distress Syndrome
  • RDS The primary etiology of RDS is attributed to insufficient amounts of pulmonary surfactant. Those at greatest risk are infants born before the 36th week of gestation having premature lung development. Neonates born at less than 28 weeks of gestation have a 60-80% chance of developing RDS. RDS is a life-threatening condition.
  • molecules of DPPC are immobilized in the form of crystalline islets and cannot re-spread onto the alveolar surface, which can greatly impair the respiratory cycle.
  • Surfactant replacement therapy has recently been used either alone or in combination with ventilation therapy. Early work with surfactant replacements used preparations of human lung surfactant obtained from lung lavage.
  • bovine lung surfactant substitutes are purified preparations of bovine and porcine lung surfactant. Like human surfactant, bovine lung surfactant preparation is complex. Sources are few and availability is limited. Further, while the use of bovine lung surfactant in neonates does not present a problem immunologically, bovine surfactant applications in adults could immunologically sensitize patients to other bovine products. Moreover, the absence of risk of transmission of the Creutzfeld-Jakob disease remains to be proven.
  • EP 050 793 discloses a combination of hexadecanol and DPPC.
  • Ventilation with liquid fluorocarbons has been proposed in U.S. Pat. No. 5,853,003, and was shown to be safe, improve lung function and recruit lung volume in patients with severe respiratory distress (Greenspan et al., Biomedical Instrumentation and Technology (1999) 33:253-259; Leach et al., New England Journal of Medicine (1996) 335:761-767).
  • the biocompatibility of fluorocarbons has been discussed (Riess, Chemical Reviews (2001) 101:2797-2919; Riess, Tetrahedron (2002) 58:4113-4131).
  • a Langmuir DPPC monolayer is accepted as a pulmonary surfactant model.
  • a DPPC monolayer undergoes a phase transition from a fluid liquid-expended state to a crystalline liquid-condensed state. Crystalline islets are thus formed due to the high cohesive energy of the DPPC molecules.
  • the molecules of DPPC involved in crystalline islets do not respread rapidly enough on the alveoli surface. For that reason, DPPC alone cannot function as an effective lung surfactant.
  • the inventors have discovered that highly fluorinated compounds, and in particular fluorocarbons, in a liquid or gaseous form, make it possible to inhibit the liquid-expended to liquid-condensed transition, and therefore prevent the formation of crystalline islets when a Langmuir phospholipid monolayer is compressed.
  • the fluorocarbon composition may be in a liquid or gaseous form, and may be administered neat as an aerosol or vaporized.
  • a preferred highly fluorinated compound is a fluorocarbon such as perfluorooctylethane (PFOE) or bis(perfluorobutyl)ethene (F-44E).
  • PFOE perfluorooctylethane
  • F-44E bis(perfluorobutyl)ethene
  • a still preferred fluorocarbon is a brominated fluorocarbon, and a still more preferred fluorocarbon is perfluorooctyl bromide (PFOB).
  • the fluorocarbon is administered in association with a phospholipid, such as dipalmitoylphosphatidylcholine (DPPC).
  • a phospholipid such as dipalmitoylphosphatidylcholine (DPPC).
  • the molecular ratio between these two components preferably ranges from 1 to 300.
  • the fluorocarbon is administered in liquid or vapor (gaseous) form, and preferably in a quantity corresponding of about 0.005 to about 4% of fluorocarbon in volume/kg body weight, preferably from about 0.005% to about 2% in volume/kg body weight.
  • the fluorocarbon may be administered neat or in the form of a water-in-fluorocarbon emulsion, or in the form of an oil-in-fluorocarbon emulsion.
  • the fluorocarbon composition may also serve as a drug delivery system. It is then contemplated that a further therapeutic agent can be dispersed in the fluorocarbon preparation.
  • the invention further provides a therapeutic composition
  • a therapeutic composition comprising a fluorocarbon and a phospholipid, and optionally a therapeutic agent, e.g. prednisone or epinephrine.
  • the composition is in the form of an emulsion comprising a continuous phase of fluorocarbon.
  • the emulsion with a continuous fluorocarbon phase contains pulmonary pharmacologically active substance such as an antibiotic, a tuberculostatic antimycobacterial agent, an anticancer agent, a pulmonary vasoactive substance, etc.
  • FIG. 1 is a graph showing the variation of the surface pressure versus the molecular area, for DPPC alone and for DPPC contacted with 200 ⁇ l of liquid PFOB.
  • the graph shows the influence of liquid PFOB on the DPPC monolayer.
  • FIG. 2 is a graph showing the surface pressure versus the molecular area, for DPPC alone and for DPPC contacted with a nitrogen atmosphere saturated with gaseous PFOB.
  • the graph shows the influence of gaseous PFOB on the DPPC monolayer.
  • FIG. 3 is a set of photographs by fluorescence microscopy showing that the crystalline islets, initially present in the DPPC monolayer compressed at 10 mN ⁇ m ⁇ 1 (A) progressively disappear with time when the monolayer is contacted with gaseous PFOB (B, C, D, visualization of the monolayer after 3, 5 and 7 min, respectively).
  • FIG. 4 is a graph showing the surface pressure versus the molecular area, for DPPC alone and for DPPC contacted with a nitrogen atmosphere saturated with gaseous bis(perfluorobutyl)ethene (F-44E).
  • the graph shows the influence of gaseous F-44E on the DPPC monolayer.
  • FIG. 5 shows the analysis by grazing incidence X-ray diffraction of the DPPC monolayer compressed at 40 mN ⁇ m ⁇ 1 before ( ⁇ ) and after ( ⁇ ) the addition of gaseous F-44E.
  • the two diffraction peaks seen in the absence of fluorocarbon are characteristics of the molecular organisation of DPPC in crystalline islets ( ⁇ ). After saturation with gaseous F-44E, one can clearly see that these peaks have disappeared ( ⁇ ), which shows the dissolution of the islets and the fluidization of the DPPC monolayer.
  • fluorocarbons may be straight, branched or cyclic, saturated or unsaturated poly- or perfluorinated hydrocarbons. These compounds may also comprise heteroatoms such as oxygen or nitrogen, or halogen atoms other than fluorine, in particular bromine. Generally, the compound is liquid or gaseous at room temperature (25° C.). Preferably, the compound has from 2 to 12 carbon atoms. There is a large number of compounds compatible with the biomedical application described.
  • fluorocarbons include brominated perfluorocarbons, such as 1-bromo-heptadecafluorooctane (C 8 F 17 Br, sometimes designated perfluorooctyl bromide or “PFOB”), 1-bromopentadecafluoroheptane (C 7 F 15 Br), and 1-bromotridecafluorohexane (C 6 F 13 Br, sometimes known as perfluorohexyl bromide or “PFHB”).
  • PFOB 1-bromo-heptadecafluorooctane
  • PFOB 1-bromopentadecafluoroheptane
  • PFHB 1-bromotridecafluorohexane
  • Other brominated fluorocarbons are disclosed in U.S. Pat. No. 3,975,512.
  • fluorocarbons having other nonfluorine substituents such as perfluorooctyl chloride, perfluorohexyl dichloride, perfluorooctyl hydride, and similar compounds having different numbers of carbon atoms.
  • Additional fluorocarbons contemplated in accordance with this invention include perfluoroalkylated ethers or polyethers, such as (CF 3 ) 2 CFO(CF 2 CF 2 ) 2 OCF(CF 3 ) 2 ; (CF 3 ) 2 CFO(CF 2 CF 2 ) 3 OCF(CF 3 ); (CF 3 )CFO(CF 2 CF 2 )F; (CF 3 ) 2 CFO(CF 2 CF 2 ) 2 F; (C 6 F 13 ) 2 O.
  • perfluoroalkylated ethers or polyethers such as (CF 3 ) 2 CFO(CF 2 CF 2 ) 2 OCF(CF 3 ) 2 ; (CF 3 ) 2 CFO(CF 2 CF 2 ) 3 OCF(CF 3 ); (CF 3 )CFO(CF 2 CF 2 )F; (CF 3 ) 2 CFO(CF 2 CF 2 ) 2 F; (C 6 F 13 ) 2 O.
  • fluorocarbon-hydrocarbon compounds such as, for example compounds having the general formula C n F 2n+1 C n′ H 2n′+1 (also called semifluorinated alkanes or -FnHn′, C n F 2n+1 OC n′ H 2n′+1 ; or C n F 2n+1 CH ⁇ CHC n′H 2n′+1 , where n and n′ are the same or different and n ranges from 4 to 10 and n′ ranges from 2 to 20.
  • C n F 2n+1 C n′ H 2n′+1 also called semifluorinated alkanes or -FnHn′, C n F 2n+1 OC n′ H 2n′+1 ; or C n F 2n+1 CH ⁇ CHC n′H 2n′+1 , where n and n′ are the same or different and n ranges from 4 to 10 and n′ ranges from 2 to 20.
  • Such compounds include, for example, perfluorooctylethane (C 8 F 17 C 2 H 5 , “PFOE”), perfluorohexylethane (C 6 F 13 C 2 H 5 , “PFHE”) and perfluorohexyldecane (C 6 F 13 C 10 H 21 , “F6H10”) or perfluorobutyl-1-undecene (C 4 F 9 CH ⁇ CHC 10 H 21 “F4H8E”).
  • esters, thioethers, and other variously modified mixed fluorocarbon-hydrocarbon compounds are also encompassed within the broad definition of “fluorocarbon” materials suitable for use in the present invention. Mixtures of fluorocarbons are also contemplated.
  • Preferred fluorocarbons are perfluorooctyl bromide (PFOB), bis(perfluorobutyl)ethene (F-44E) and perfluorooctylethane (PFOE).
  • PFOB perfluorooctyl bromide
  • F-44E bis(perfluorobutyl)ethene
  • PFOE perfluorooctylethane
  • a therapeutic agent may be combined (e.g. dispersed) with the fluorocarbon.
  • Suitable therapeutic agents include, but are not limited to, antibiotics such as gentamicin, erythromycin and doxycycline; tuberculostatic antimycobacterials such as pyrazinamide, ethambutol and isoniazid; anticancerous agents such as cis-platinum, cyclophosphamide, 5-fluorouracyl and doxorubicin; pulmonary vasoactive substances and regulators of pulmonary hypertension such as tolazoline; respiratory stimulants such as doxapram; vasoactive bronchodilators or bronchostrictors such as acetylcholine, priscoline, epinephrine and theophylline; mucolytic agents such as acetylcysteine; steroids such as cortisone or prednisone; antiviral agents such as ribavirin.
  • antibiotics such as gentamicin, erythromycin and doxycycline
  • fluorocarbons There exist abundant data that demonstrate the biocompatibility of fluorocarbons. They are amenable to sterilization techniques. For example, they can generally be heat-sterilized (such as by autoclaving) or sterilized by radiation. In addition, sterilization by ultrafiltration is also contemplated.
  • the fluorocarbon can be provided as a liquid or in a gaseous form.
  • Inhalation or forced (positive pressure) introduction either nasal or oral, of the fluorocarbon composition
  • Microparticles can be inhaled from standard aerosol delivery systems that are well known in the art.
  • the patient may receive a particulate suspension which is placed into an air stream such as by injection of the dispersed composition into a positive pressure ventilation tube or into an endotracheal tube at the moment of inspiration or when air is forced into the lungs. Metered dosages may be mechanically injected into such devices.
  • the fluorocarbon composition may be dispersed in air by using the Venturi effect, where air is moved at right angles across a Venturi tube causing the fluorocarbon composition to be drawn through the tube and dispersed into the air that is inhaled or mechanically introduced into the lungs.
  • Pulsatile delivery of the fluorocarbon composition in a volume of gas and inhalation of the aerosolized bolus is also known in the art as described in PCT published application WO 94/07514, and the delivery techniques described therein can be used in the present invention.
  • Liquid compositions of fluorocarbons may be directed to specific regions of the patient's pulmonary air passages by a number of different conventional means, such as a bronchoscope, a catheter, and the like.
  • the fluorocarbon introduced into the patient's lung may be in liquid or vapor form.
  • the quantity of fluorocarbon composition administered may correspond to about 0.005 to about 4% of liquid fluorocarbon in volume/kg body weight, preferably from about 0.005% to about 2%.
  • the method of the invention improves the fluidity of the pulmonary surfactant, mainly by preventing the formation of crystalline islets of phospholipid, such as crystalline islets of DPPC, and/or by respreading the phospholipid islets that might have formed.
  • ARDS in adults caused by severe hypovolemic shock, lung contusion, diver's lung, post-traumatic respiratory distress, post-surgical atelectasis, septic shock, multiple organ failure, Mendelssohn's disease, obstructive lung disease, pneumonia, pulmonary oedema or any other condition resulting in lung surfactant deficiency or respiratory distress are all candidates for fluorocarbon supplementation and the method of the invention.
  • Treatment of pulmonary fibrosis, emphysema, and chronic bronchitis can all benefit from fluorocarbon therapy as proposed herein.
  • the fluorocarbon is administered with a surfactant agent, e.g. a lipid or a phospholipid.
  • the surfactant agent may be an amphiphilic molecule or a mixture of amphiphilic molecules, or may be a preparation of artificial lung surfactant, or may be extracted from human or mammal lung surfactant.
  • the surfactant agent is a phospholipid.
  • the phospholipid may be a mixture of phospholipids. It is preferably selected from the group consisting of native pulmonary surfactant phospholipids, i.e.
  • the fluorocarbon may also be administered with a mixture of phospholipids and glycoproteins, such as SP-A, SP-B, SP-C and SP-D, which are components of the native pulmonary surfactant composition. Fluorocarbon compounds are generally poorly soluble in water. Therefore, it is possible to prepare emulsions comprising a fluorocarbon compound, a phospholipid and water.
  • Such emulsions allow easy administration of both one or more fluorocarbons and one or more phospholipids at controlled dosage.
  • the emulsions may be prepared by mixing an aqueous phase and, dissolved or dispersed in the water, the phospholipid, with the fluorocarbon phase, optionally in presence of an additional suitable surfactant.
  • One or both phases may further contain one or more therapeutic agents, as described above.
  • Appropriate surfactants include in particular fluorinated amphiphilic compounds such as fluorinated dimorpholinophosphate.
  • the water phase is added slowly to the fluorinated phase containing an emulsifier, in particular a fluorinated surfactant.
  • an emulsifier in particular a fluorinated surfactant.
  • the resulting pre-emulsion may then be homogenized, using procedures that are well known as such, in order to yield an emulsion with a narrow droplet size distribution.
  • the fluorocarbon/phospholipid molecular ratio between these two components preferably ranges from 1 to 300. In a preferred embodiment, the molecular ratio between phospholipid and the fluorocarbon ranges from 1 to 50.
  • composition useful in the invention is a therapeutic composition comprising an emulsion of water in PFOB that contains DPPC.
  • Another example of composition is a therapeutic composition comprising an emulsion of water in PFOE that contains DPPC.
  • compositions include these above compositions supplemented with a pulmonary active agent, such as prednisone or epinephrine.
  • a pulmonary active agent such as prednisone or epinephrine.
  • the invention thus contemplates the use of a fluorocarbon, optionally in combination with a surfactant agent, especially a phospholipid, e.g. a phospholipid of a native pulmonary surfactant, for the manufacture of a medicament intended for improving the spreadability and/or the fluidity of the native pulmonary surfactant in patients in need of such treatment.
  • a surfactant agent especially a phospholipid, e.g. a phospholipid of a native pulmonary surfactant, for the manufacture of a medicament intended for improving the spreadability and/or the fluidity of the native pulmonary surfactant in patients in need of such treatment.
  • the patients may be a human or a non-human animal, preferably a mammal. It may be a new-born patient, an infant, a child or an adult of any age.
  • the monolayer of native pulmonary surfactant was modeled by a Langmuir monolayer of DPPC.
  • the DPPC molecules were spread using a spreading solvent onto the surface of water contained in a trough coated with Teflon®. After evaporation of the solvent, the DPPC molecules were progressively compressed using two mobile Teflon® barriers. The variation of the surface pressure was measured as a function of the compression by a pressure sensor such as a Wilhelmy blade.
  • FIG. 1 compares the compression isotherms of a DPPC monolayer alone and in contact with the fluorocarbon. In absence of fluorocarbon, one notes the presence of a plateau reflecting the coexistence of the expanded liquid state (fluid phase) and the condensed liquid state (crystalline islets). This plateau disappeared totally in presence of fluorocarbon.
  • the DPPC monolayer is totally fluid.
  • the DPPC monolayer is totally fluid.
  • Fluorescence microscopy makes it possible to visualize the dissolution of crystalline islets of DPPC molecules when the monolayer is contacted with gaseous PFOB ( FIG. 3A ). After 3 minutes, the size of the islets becomes small ( FIG. 3B ) and after 5 minutes, the phenomenon is becoming accurate: the DPPC monolayer has almost completely re-spread ( FIG. 3C ) and after 7 minutes, the islets have completely disappeared ( FIG. 3D ).
  • PFOB sterile PFOB
  • a vaporization kit for Omron CX3 aerosol optionally fitted with a vaporization kit for Omron CX3, or any other vaporization system (Hudson TUp-draftII/Pulmo-aide, Airlife Mysty/Pulmo-Aide, Respirgard/Pulmo-aide, etc).
  • PFOB was then vaporized according to the recommendations of the manufacturer.
  • F8H11DMP 3% w/v perfluorooctyl(undecyl)dimorpholinophosphate
  • 95% v/v PFOB 95% v/v PFOB was prepared.
  • F8H11DMP 3 g was dispersed in 95 ml of PFOB using a low energy mixer (Ultra-Turrax® T25 equipped with the S25N25F, Ika-Labortechnik, Stanfen, Germany) at a temperature below 40° C. 5 ml of physiological water were then added dropwise under constant agitation.
  • the pre-emulsion thus obtained was homogenized under high pressure using a Microfluidizer® 110T (Microfluidics, New Jersey, USA) for about 10 minutes at a temperature below 40° C.
  • the emulsion thus obtained was opalescent, and the mean size of the water droplets was 60 ⁇ 5 nm (3000 Zeta Sizer, Malvern Instrument).
  • This emulsion was sterilized by filtration through a 0.22 ⁇ m membrane before bottling in 10 ml flasks (with 8% hold-up volume).
  • the mean size of the water droplets after one-year storage at 25° C. was 100 ⁇ 7 nm.
  • the pre-emulsion thus obtained was homogenized under high pressure using a Microfluidizer® 110T (Microfluidics, New Jersey, USA) for about 10 minutes at a temperature below 40° C. as described in Example 1.
  • the emulsion thus obtained was opalescent, and the mean size of the water droplets was 70 ⁇ 5 nm (3000 Zeta Sizer, Malvern Instrument). This emulsion was sterilized, bottled and stored as described in Example 7.
  • the mean size of droplets after one-year storage at 25° C. was 120 ⁇ 10 nm.
  • the emulsion is prepared following the protocol of Example 8, using PFOE instead of PFOB. An opalescent emulsion is obtained.
  • the mean size of the water droplets was 65 ⁇ 5 nm (3000 Zeta Sizer, Malvern Instrument). The emulsion was sterilized, bottled and stored as described in Example 7. The mean size of the droplets after one-year storage at 25° C. was 110 ⁇ 10 nm.
  • An emulsion containing 5% v/v isotonic buffer (pH 3.0-3.5), 0.02 w/v epinephrine, 1% w/v DPPC, 3% w/v F8H11DMP (perfluorooctyl)undecyl dimorpholinophosphate) and 95% v/v PFOB is obtained as follows: 0.75 g F8H11DMP were dispersed in 23.75 ml of PFOB as described in Example 7. Separately, 0.25 g DPPC and 5 mg epinephrine were co-dispersed in 1.25 ml of isotonic buffer. This dispersion was added dropwise to the fluorinated phase under constant agitation.
  • the pre-emulsion obtained was homogenised under high pressure with an Emulsiflex-B3® (Avestin, Ottawa, Canada).
  • An opalescent emulsion was obtained, with water droplets of a mean size of 40 ⁇ 3 nm (3000 Zeta Sizer, Malvern Instrument). This emulsion was sterilized, bottled and stored as described in Example 7.
  • the mean size of the droplets after one-year storage at 25° C. was 70 ⁇ 5 nm.
  • the emulsion was prepared following the protocol of Example 10, using PFOE instead of PFOB.
  • An opalescent emulsion was obtained with droplets of a mean size of 55 ⁇ 5 nm (3000 Zeta Sizer, Malvern Instrument).
  • the emulsion was sterilized, bottled and stored as described in Example 7.
  • the mean size of the droplets after one year storage at 25° C. was 118 ⁇ 10 nm.
  • An emulsion containing 4.7% v/v physiological water, 0.02 w/v prednisone, 20% v/v perfluorobutyl-1-undecene (F4H8E), 4.7% v/v perfluorohexyldecane (F6H10), 4.8 w/v perfluorooctyl(undecyl)dimorpholinophosphate (F8H11DMP) and 67% v/v PFOB is obtained as follows: 2 mg prednisone are dissolved in 2 ml of F4H8E under agitation and moderate heating.
  • the emulsion was prepared following the protocol of Example 12, using PFOE instead of PFOB.
  • An opalescent emulsion is obtained with droplets of a mean size of 146 ⁇ 15 nm (3000 Zeta Sizer, Malvern Instrument).
  • the emulsion was sterilized, bottled and stored as described in Example 12.
  • the mean size of the water droplets after six-months storage at 25° C. was 210 ⁇ 25 nm.
  • Example 7 The emulsion prepared according to Example 7 was vaporised following the protocol described in Example 4.
  • Example 8 The emulsion prepared according to Example 8 was aerosolized following the protocol described in Example 5.
  • Example 10 The emulsion prepared according to Example 10 was aerosolized following the protocol described in Example 5.
  • Example 12 The emulsion prepared according to Example 12 is aerosolized following the protocol described in Example 5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US11/578,673 2004-04-19 2005-04-18 Lung Surfactant Supplements Abandoned US20080019926A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/578,673 US20080019926A1 (en) 2004-04-19 2005-04-18 Lung Surfactant Supplements

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56369004P 2004-04-19 2004-04-19
US11/578,673 US20080019926A1 (en) 2004-04-19 2005-04-18 Lung Surfactant Supplements
PCT/IB2005/001020 WO2005099718A1 (fr) 2004-04-19 2005-04-18 Complements de surfactant pulmonaire

Publications (1)

Publication Number Publication Date
US20080019926A1 true US20080019926A1 (en) 2008-01-24

Family

ID=34965537

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/578,673 Abandoned US20080019926A1 (en) 2004-04-19 2005-04-18 Lung Surfactant Supplements

Country Status (5)

Country Link
US (1) US20080019926A1 (fr)
EP (1) EP1740189B1 (fr)
CA (1) CA2563544A1 (fr)
ES (1) ES2387619T3 (fr)
WO (1) WO2005099718A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080127968A1 (en) * 2006-10-26 2008-06-05 Next Breath Llc Phospholipid-based inhalation system
US20100008996A1 (en) * 2008-04-18 2010-01-14 Novaliq Gmbh Inhalative and instillative use of semifluorinated alkanes as an active substance carrier in the intrapulmonary area
US20120121516A1 (en) * 2009-07-17 2012-05-17 Centre National De La Recherche Scientifique- Cnrs Emulsion Activatable by Ultrasounds and Method for Producing Same
EP2587917A4 (fr) * 2010-07-01 2015-05-06 Mtm Res Llc Thérapies au moyen d'émulsions fluorochimiques antifibroblastiques
US11413323B2 (en) 2018-10-12 2022-08-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US11510855B2 (en) 2018-09-27 2022-11-29 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
USRE49758E1 (en) 2012-01-23 2023-12-19 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
US11987623B2 (en) 2013-07-23 2024-05-21 Novaliq Gmbh Stabilized antibody compositions
US12029757B2 (en) 2018-09-27 2024-07-09 Dermaliq Therapeutics, Inc. Lipid barrier repair
US12128010B2 (en) 2015-09-30 2024-10-29 Novaliq Gmbh Semifluorinated compounds and their compositions
US12150955B2 (en) 2017-04-21 2024-11-26 Dermaliq Therapeutics, Inc. Iodine compositions
US12226422B2 (en) 2018-04-27 2025-02-18 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053673A2 (fr) 2005-11-01 2007-05-10 E. I. Du Pont De Nemours And Company Compositions de solvant comprenant des hydrocarbures fluores insatures
US20070098646A1 (en) 2005-11-01 2007-05-03 Nappa Mario J Aerosol propellants comprising unsaturated fluorocarbons
KR20100017378A (ko) 2007-04-27 2010-02-16 이 아이 듀폰 디 네모아 앤드 캄파니 Ｚ-1,1,1,4,4,4-헥사플루오로-2-부텐의 공비 및 공비-유사 조성물
AU2008261695B2 (en) 2007-06-12 2013-05-30 The Chemours Company Fc, Llc. Azeotropic and azeotrope-like compositions of E-1,1,1,4,4,4-hexafluoro-2-butene
CA2695229C (fr) 2007-09-06 2016-05-10 E.I. Du Pont De Nemours And Company Compositions azeotropes et de type azeotrope de e-1,1,1,4,4,5,5,5-octafluoro-2-pentene
US8299137B2 (en) 2007-11-29 2012-10-30 E I Du Pont De Nemours And Company Compositions and use of cis-1,1,1,4,4,4-hexafluoro-2-butene foam-forming composition in the preparation of polyisocyanate-based forms
CA2708274C (fr) 2007-12-19 2016-10-18 E. I. Du Pont De Nemours And Company Compositions moussantes contenant des melanges azeotropiques ou de type azeotropique contenant du z-1,1,1,4,4,4-hexafluoro-2-butene et leurs applications dans la preparation de mousses a base de polyisocyanate
EP2335735A1 (fr) * 2009-12-14 2011-06-22 Novaliq GmbH Composition pharmaceutique pour le traitement de la kératoconjonctivite sèche
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
US8821749B2 (en) 2010-04-26 2014-09-02 E I Du Pont De Nemours And Company Azeotrope-like compositions of E-1,1,1,4,4,4-hexafluoro-2-butene and 1-chloro-3,3,3-trifluoropropene
EP2444063A1 (fr) 2010-10-20 2012-04-25 Novaliq GmbH Compositions pharmaceutiques liquides pour l'administration de principes actifs
EP2462921A1 (fr) 2010-11-11 2012-06-13 Novaliq GmbH Compositions pharmaceutiques liquides pour le traitement d'une maladie de la chambre postérieure de l'oeil
AU2012260788B2 (en) 2011-05-25 2017-01-19 Dermaliq Therapeutics, Inc. Pharmaceutical composition for administration to nails
PL3192501T3 (pl) 2011-05-25 2020-11-02 Novaliq Gmbh Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach
PL3181119T3 (pl) 2012-09-12 2020-01-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki
EP2895158B1 (fr) 2012-09-12 2019-11-20 Novaliq GmbH Compositions comprenant des mélanges d'alcanes semi-fluorés
PL3722274T3 (pl) 2015-09-30 2023-12-04 Novaliq Gmbh Związki semifluorowane
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
EP3515467B1 (fr) 2016-09-23 2023-11-29 Novaliq GmbH Composition ophtalmique comprenant ciclosporine
CN110650734B (zh) 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
CN120022260A (zh) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5733526A (en) * 1995-12-14 1998-03-31 Alliance Pharmaceutical Corp. Hydrocarbon oil/fluorochemical preparations and methods of use
US5853003A (en) * 1991-05-03 1998-12-29 Alliance Pharmaceutical Corp. Treatment and diagnosis of respiratory disorders using fluorocarbon liquids
US6113919A (en) * 1991-07-17 2000-09-05 Alliance Pharmaceutical Corp. Preparations comprising a fluorocarbon or a highly fluorinated compound and a lipophilic/fluorophilic compound and their uses
US20010046474A1 (en) * 1997-09-29 2001-11-29 Weers Jeffry G. Stabilized preparations for use in metered dose inhalers
US20020037316A1 (en) * 2000-05-10 2002-03-28 Weers Jeffry G. Phospholipid-based powders for drug delivery
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US7195752B2 (en) * 2001-08-03 2007-03-27 Glaxo Group Limited Surfactant compounds and uses thereof
US7273416B2 (en) * 2003-03-19 2007-09-25 Ian Peek Golf training apparatus
US7473416B2 (en) * 1997-12-03 2009-01-06 Britannia Pharmaceuticals, Ltd. Medicaments for asthma treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020159951A1 (en) * 1997-05-06 2002-10-31 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
JP2006516545A (ja) * 2003-02-04 2006-07-06 クリサリス テクノロジーズ インコーポレイテッド パーフルオロカーボン及びハイドロフルオロカーボン製剤及びその製法及び使用法
US20050214224A1 (en) * 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853003A (en) * 1991-05-03 1998-12-29 Alliance Pharmaceutical Corp. Treatment and diagnosis of respiratory disorders using fluorocarbon liquids
US6113919A (en) * 1991-07-17 2000-09-05 Alliance Pharmaceutical Corp. Preparations comprising a fluorocarbon or a highly fluorinated compound and a lipophilic/fluorophilic compound and their uses
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5733526A (en) * 1995-12-14 1998-03-31 Alliance Pharmaceutical Corp. Hydrocarbon oil/fluorochemical preparations and methods of use
US20010046474A1 (en) * 1997-09-29 2001-11-29 Weers Jeffry G. Stabilized preparations for use in metered dose inhalers
US7473416B2 (en) * 1997-12-03 2009-01-06 Britannia Pharmaceuticals, Ltd. Medicaments for asthma treatment
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US20020037316A1 (en) * 2000-05-10 2002-03-28 Weers Jeffry G. Phospholipid-based powders for drug delivery
US7195752B2 (en) * 2001-08-03 2007-03-27 Glaxo Group Limited Surfactant compounds and uses thereof
US7273416B2 (en) * 2003-03-19 2007-09-25 Ian Peek Golf training apparatus

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206687B2 (en) * 2006-10-26 2012-06-26 Next Breath, Llc Phospholipid-based inhalation system
US8591954B2 (en) 2006-10-26 2013-11-26 Next Breath, Llc Phospholipid-based inhalation system
US20080127968A1 (en) * 2006-10-26 2008-06-05 Next Breath Llc Phospholipid-based inhalation system
US20100008996A1 (en) * 2008-04-18 2010-01-14 Novaliq Gmbh Inhalative and instillative use of semifluorinated alkanes as an active substance carrier in the intrapulmonary area
US8986738B2 (en) * 2008-04-18 2015-03-24 Novaliq Gmbh Inhalative and instillative use of semifluorinated alkanes as an active substance carrier in the intrapulmonary area
US20120121516A1 (en) * 2009-07-17 2012-05-17 Centre National De La Recherche Scientifique- Cnrs Emulsion Activatable by Ultrasounds and Method for Producing Same
EP2587917A4 (fr) * 2010-07-01 2015-05-06 Mtm Res Llc Thérapies au moyen d'émulsions fluorochimiques antifibroblastiques
USRE49758E1 (en) 2012-01-23 2023-12-19 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
US11987623B2 (en) 2013-07-23 2024-05-21 Novaliq Gmbh Stabilized antibody compositions
US12128010B2 (en) 2015-09-30 2024-10-29 Novaliq Gmbh Semifluorinated compounds and their compositions
US12150955B2 (en) 2017-04-21 2024-11-26 Dermaliq Therapeutics, Inc. Iodine compositions
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
US12226422B2 (en) 2018-04-27 2025-02-18 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
US11510855B2 (en) 2018-09-27 2022-11-29 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
US12029757B2 (en) 2018-09-27 2024-07-09 Dermaliq Therapeutics, Inc. Lipid barrier repair
US11413323B2 (en) 2018-10-12 2022-08-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12059449B2 (en) 2018-10-12 2024-08-13 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization

Also Published As

Publication number Publication date
EP1740189A1 (fr) 2007-01-10
CA2563544A1 (fr) 2005-10-27
ES2387619T3 (es) 2012-09-27
WO2005099718A1 (fr) 2005-10-27
EP1740189B1 (fr) 2012-06-13

Similar Documents

Publication Publication Date Title
EP1740189B1 (fr) Complements de surfactant pulmonaire
US6289892B1 (en) Partial liquid breathing of fluorocarbons
CN101559229B (zh) 在肺内区域作为活性物质载体的半氟化烷的吸入式和滴注式用途
AU721759B2 (en) Continuous fluorochemical microdispersions for the delivery of pharmaceutical agents
US5980936A (en) Multiple emulsions comprising a hydrophobic continuous phase
Riess et al. Advanced fluorocarbon-based systems for oxygen and drug delivery, and diagnosis
JPH10500976A (ja) 安定なフルオロカーボン逆エマルションおよび複エマルション
US6770619B2 (en) Lung surfactant compositions with dynamic swelling behavior
Weers A physicochemical evaluation of perfluorochemicals for oxygen transport applications
EP0689422B1 (fr) Emulsions de fluorocarbones avec une propension moindre a pieger des gaz dans les poumons
US20120321586A1 (en) Surfactant composition
EP0553272B1 (fr) Agent tensio-actif synthetique pour le traitement des poumons
EP0841896B1 (fr) Gels inverses comprenant une phase fluoree continue
Gerber et al. Impact of perfluorooctylethane on the formation of a semi-crystalline liquid-condensed phase in a phospholipid monolayer and of perfluorooctyl bromide on the adsorption of albumin on such a monolayer
AU710142B2 (en) Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
AU704024B2 (en) Perfluorocarbon associated gas exchange and partial liquid breathing of fluorocarbons
HK1014149B (en) Partial liquid breathing of fluorocarbons
AU6651100A (en) Continuous fluorochemical microdispersions for the delivery of pharmaceutical agents
AU4013099A (en) Perfluorocarbon associated gas exchange and partial liquid breathing of fluorocarbons

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITE LOUIS PASTEUR INDUSTRIE, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KRAFFT, MARIE-PIERRE;VANDAMME, THIERRY;GERBER, FREDERIC;AND OTHERS;REEL/FRAME:018675/0839;SIGNING DATES FROM 20061010 TO 20061011

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KRAFFT, MARIE-PIERRE;VANDAMME, THIERRY;GERBER, FREDERIC;AND OTHERS;REEL/FRAME:018675/0839;SIGNING DATES FROM 20061010 TO 20061011

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION